COHANCECohance Lifesciences Ltd.

    Cohance Lifesciences Ltd: results and news

    Every Cohance Lifesciences Ltd filing with the NSE and BSE that Blacklitt has written about, explained in plain words and linked to the filing, newest first: earnings, management change.

    2 articles · Pharma CDMO · Latest 6 Nov 2026

    Two clear glass test tubes lying on a grey surface, one with a few dark specks inside.

    COHANCECohance Lifesciences Ltd.

    Cohance Lifesciences Q2 FY27 Results: Consolidated Net Profit ₹2.27 Crore on Total Income of ₹489 Crore

    Cohance Lifesciences (NSE: COHANCE) reported consolidated total income of ₹489.06 crore and consolidated net profit of ₹2.27 crore for the quarter ended 30 Sep 2026, it said in a filing on 06 Nov 2026. Net profit attributable to shareholders was ₹15.22 crore, and consolidated profit before tax was negative at ₹10.75 crore. Standalone total income was ₹437.26 crore and standalone net profit ₹13.27 crore.

    • Earnings
    • Pharma CDMO

    Blacklitt Research4 min read